Functional interactions between estrogen and insulin-like growth factor-I in the regulation of alpha 1B-adrenoceptors and female reproductive function.
The ovarian hormone estradiol (E(2)) and insulin-like growth factor-I (IGF-I) interact in the CNS to regulate neuroendocrine function and synaptic remodeling. Previously, our laboratory showed that 2 d E(2) treatment induces alpha(1B)-adrenoceptor expression and promotes IGF-I enhancement of alpha(1)-adrenoceptor potentiation of cAMP accumulation in the preoptic area (POA) and hypothalamus (HYP). This study examined the hypothesis that E(2)-dependent aspects of female reproductive function, including alpha(1B)-adrenoceptor expression and function in the POA and HYP, are mediated by brain IGF-I receptors (IGF-IRs) in female rats. Ovariohysterectomized rats were implanted with a guide cannula aimed at the third ventricle and treated in vivo with vehicle or E(2) daily for 2 d before experimentation. Intracerebroventricular infusions of JB-1, a selective IGF-IR antagonist, were administered every 12 hr beginning 1 hr before the first E(2) injection. Administration of JB-1 during E(2) priming completely blocks hormone-induced luteinizing hormone release and partially inhibits hormone-dependent reproductive behavior. Reproductive behavior is restored by intracerebroventricular infusion of 8-bromo-cGMP, the second messenger implicated in alpha(1)-adrenergic facilitation of lordosis. In addition, blockade of IGF-IRs during E(2) priming prevents E(2)-induced increases in alpha(1B)-adenoceptor binding density and abolishes acute IGF-I enhancement of NE-stimulated cAMP accumulation in HYP and POA slices. These data document the existence of a novel mechanism by which IGF-I participates in the remodeling of noradrenergic receptor signaling in the HYP and POA after E(2) treatment. These events may help coordinate the timing of ovulation with the expression of sexual receptivity.
Quesada
Arnulfo
A
Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Etgen
Anne M
AM
D058668:Adrenergic alpha-1 Receptor Antagonists; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D006152:Cyclic GMP / Q000031:analogs & derivatives* / Q000494:pharmacology; D004958:Estradiol / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007044:Hysterectomy; D066298:In Vitro Techniques; D007276:Injections, Intraventricular; D007334:Insulin-Like Growth Factor I / Q000378:metabolism* / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D010052:Ovariectomy; D010455:Peptides / Q000008:administration & dosage; D011187:Posture; D011224:Prazosin / Q000378:metabolism; D011301:Preoptic Area / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*; D012098:Reproduction / Q000502:physiology*; D012726:Sexual Behavior, Animal / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D058668:Adrenergic alpha-1 Receptor Antagonists; D010455:Peptides; D018340:Receptors, Adrenergic, alpha-1; C016276:8-bromocyclic GMP; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1; D006152:Cyclic GMP; D009638:Norepinephrine; D011224:Prazosin